H.C. Wainwright lowered the firm’s price target on Clearside Biomedical (CLSD) to $5 from $6 and keeps a Buy rating on the shares following the Q1 report. The firm’s estimated market value of the company remains unchanged, but the projected shares outstanding have increased.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLSD:
- Clearside Biomedical Reports Q1 2025 Financial Progress
- Clearside Biomedical: Undervalued Opportunity with Strategic Partnerships and Promising CLS-AX Advancements
- Clearside Biomedical reports Q1 EPS (11c), consensus (11c)
- Clearside Biomedical announces six presentations related to CLS-AX
- Buy Rating for Clearside Biomedical Backed by Promising Trial Results and FDA Alignment